Reducing Breast Cancer Risk with COX-2 Inhibitors
Author Information
Author(s): Harris Randall E, Beebe-Donk Joanne, Alshafie Galal A
Primary Institution: The Ohio State University College of Medicine and Public Health
Hypothesis
Do selective COX-2 inhibitors reduce the risk of breast cancer?
Conclusion
Selective COX-2 inhibitors significantly reduce the risk of breast cancer by 71%.
Supporting Evidence
- Selective COX-2 inhibitors showed a significant risk reduction for breast cancer.
- Regular aspirin and ibuprofen also reduced breast cancer risk.
- Acetaminophen did not affect breast cancer risk.
Takeaway
Taking certain medications called COX-2 inhibitors can help lower the chances of getting breast cancer.
Methodology
A case-control study comparing 323 breast cancer patients with 649 cancer-free controls.
Potential Biases
Potential bias due to the reliance on self-reported medication use.
Limitations
The study is limited by the short exposure window to COX-2 inhibitors and the recall of one of the drugs.
Participant Demographics
Participants included 323 breast cancer patients and 649 matched controls based on age, race, and county.
Statistical Information
P-Value
0.29
Confidence Interval
0.14–0.59
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website